| 1 |
NCT03189043 |
Not yet recruiting |
Controlled Crossover Study of AIONX Antimicrobial Surface for the Prevention of Healthcare-associated Infections |
- Healthcare Associated Infection
|
- Device: Antimicrobial Surface
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Healthcare-Associated Infections
- 30-day Readmission for infection
|
10000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03189043 |
7371 |
|
July 1, 2017 |
October 1, 2017 |
October 1, 2017 |
June 16, 2017 |
June 16, 2017 |
|
|
|
| 2 |
NCT03658746 |
Not yet recruiting |
Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection |
- Helicobacter Pylori Infection
|
- Drug: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)
- Drug: one proton pump inhibitor, colloidal bismuth pectin
- Drug: two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Eradication rates
- The rates of adverse events happening
- The rates of improving dyspepsia symptoms after helicobacter pylori eradication.
- The rates of good compliance.
|
400 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03658746 |
2018SDU-QILU-G003 |
|
January 1, 2019 |
December 31, 2019 |
April 30, 2020 |
September 5, 2018 |
December 24, 2018 |
|
- Qilu hosipital
Jinan, Shandong, China
|
|
| 3 |
NCT03265834 |
Recruiting |
CABI: Antibiotic Duration for Complicated Intra-ABdominal Infection |
- Complicated Intraabdominal Infections
|
- Other: < 10 days of antibiotics
- Other: 28 days of antibiotics
|
Interventional
|
Phase 2 |
- University of Leeds
- The Leeds Teaching Hospitals NHS Trust
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of participants willing to be randomised, the willingness of clinicians to allow participants to be recruited & follow up rates.
- Number of participants who have their antibiotic therapy changed as a consequence of allocation to a certain treatment arm.
- The number of participants who relapse after treatment of complicated intra-abdominal infection.
- (and 9 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03265834 |
MB16/156 |
CABI |
August 1, 2017 |
March 31, 2018 |
March 31, 2018 |
August 29, 2017 |
August 29, 2017 |
|
- Leeds Teaching Hospitals NHS Trust
Leeds, Yorkshire, United Kingdom
|
|
| 4 |
NCT01994538 |
Recruiting |
Seven vs. 14 Days Treatment for Male Urinary Tract Infection |
|
- Other: Longer therapy duration
- Other: Shorter therapy duration
|
Interventional
|
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Resolution of UTI symptoms 14 days after completing active antimicrobial therapy
- Recurrent UTI within 28 days of completing active study medication
- Adverse drug event in the 28 days after completing study medication
- Intestinal carriage of antimicrobial-resistant Gram negative bacilli
|
290 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01994538 |
CLIN-008-13S
I01BX007080 |
|
April 24, 2014 |
December 31, 2019 |
December 31, 2019 |
November 25, 2013 |
February 15, 2019 |
|
- Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota, United States - Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas, United States
|
|
| 5 |
NCT03256825 |
Recruiting |
Rapid Urinary Tract Infection Diagnosis and Real-time Antimicrobial Stewardship Decision Support |
|
- Diagnostic Test: Rapid diagnostics alone
- Other: Real-time antimicrobial stewardship decision support
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- All-cause 30-day mortality
- Adherence to guidelines for empirical therapy
- Total antibiotic consumption in intervention groups and control group compared
- (and 10 more...)
|
550 |
All |
18 Years and older (Adult, Older Adult) |
NCT03256825 |
RUDE/01-2016 |
RUDE |
September 1, 2017 |
March 31, 2019 |
March 31, 2019 |
August 22, 2017 |
May 16, 2018 |
|
- Molde Hospital
Molde, Norway - Ålesund Hospital
Ålesund, Norway
|
|
| 6 |
NCT03565484 |
Not yet recruiting |
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection |
- Helicobacter Pylori Infection
|
- Drug: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)
- Drug: one proton pump inhibitor(PPI)
- Drug: two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)
- (and 2 more...)
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Eradication rates in 2 groups
- The rate of improving dyspepsia symptoms after Helicobacter pylori eradication.
|
400 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03565484 |
2017SDU-QILU-G004 |
|
August 1, 2018 |
December 30, 2019 |
April 30, 2020 |
June 21, 2018 |
June 21, 2018 |
|
- Qilu hosipital
Jinan, Shandong, China
|
|
| 7 |
NCT03571230 |
Not yet recruiting |
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication. |
- Helicobacter Pylori Infection
- Antimicrobial Susceptibility Testing
|
- Drug: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)
- Drug: two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)
- Drug: one proton pump inhibitor(PPI)
- (and 2 more...)
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Eradication rates in 2 groups
- The rate of improving dyspepsia symptoms after Helicobacter pylori eradication.
- The rate of adverse events happening
- (and 2 more...)
|
400 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03571230 |
2017SDU-QILU-G003 |
|
July 1, 2018 |
December 30, 2019 |
January 30, 2020 |
June 27, 2018 |
June 27, 2018 |
|
- Xiuli Zuo
Jinan, Shandong, China
|
|
| 8 |
NCT03633188 |
Recruiting |
Stool Biobanking and Impact of Antimicrobials on the Gut Microbiota in Patients With Bone and Joint Infection |
|
- Biological: Patients treated by antibiotherapy
|
Interventional
|
Not Applicable |
- Hospices Civils de Lyon
- University of Lyon
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- change in the gut microbiota after treatment
- Assessment of the evolution of intensity of Diarrheic Symptoms
- Assessment of the evolution of frequency of Diarrheic Symptoms
- (and 6 more...)
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT03633188 |
69HCL17_0652
2017-A02813-50 |
GUMIBONE |
July 19, 2018 |
December 2019 |
December 2019 |
August 16, 2018 |
January 17, 2019 |
|
- Hôpital de la Croix Rousse-Service de chirurgie orthopédique
Lyon, France - Hôpital de la Croix Rousse-Service des Maladies Infectieuses et Tropicales
Lyon, France - Centre Hospitalier Lyon Sud-Service de Chirurgie Orthopédique
Pierre Benite, France - Centre Hospitalier Lyon Sud-Service des maladies infectieuses
Pierre Bénite, France
|
|
| 9 |
NCT02255305 |
Recruiting |
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI |
- Clostridium Difficile Infection
|
- Biological: FMT
- Drug: Antimicrobials
|
Interventional
|
Phase 2 |
- NorthShore University HealthSystem
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Resolution of Diarrhea
- Time to Clinical Resolution of Symptoms
- Hospital Length of Stay
- Readmission and Mortality
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02255305 |
EH 14-331 |
|
January 2015 |
September 2019 |
December 2019 |
October 2, 2014 |
April 18, 2018 |
|
- NorthShore University HealthSystem
Evanston, Illinois, United States
|
|
| 10 |
NCT03113344 |
Recruiting |
Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases |
|
- Drug: cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
|
Observational
|
|
- Beijing Children's Hospital
- Shandong University
- Robert Debré Hospital
- Rennes University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- maximum concentration (Cmax)
- time to achieve maximum concentration (Tmax)
- absorption rate constant (ka)
- (and 2 more...)
|
800 |
All |
up to 18 Years (Child, Adult) |
NCT03113344 |
BCH_PPK002
Yu-Jie Qi
Wei Zhao
Hui Qi
Fei Jin
Evelyne Jacqz-Aigrain
Stephanie Leroux |
|
June 21, 2017 |
October 1, 2025 |
December 31, 2025 |
April 13, 2017 |
December 19, 2017 |
|
- Beijing Children's Hospital of Capital Medical University
Beijing, China
|
|
| 11 |
NCT03643497 |
Recruiting |
Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases |
|
- Drug: anti-infective drugs
|
Observational
|
|
- Beijing Children's Hospital
- Shandong University
- Robert Debré Hospital
- Rennes University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- maximum concentration (Cmax)
- time to achieve maximum concentration (Tmax)
- absorption rate constant (ka)
- (and 2 more...)
|
800 |
All |
up to 18 Years (Child, Adult) |
NCT03643497 |
BCH_PPK004 |
|
July 1, 2018 |
September 30, 2021 |
December 31, 2021 |
August 22, 2018 |
August 23, 2018 |
|
- Beijing Children's Hospital of Capital Medical University
Beijing, China
|
|
| 12 |
NCT03341273 |
Recruiting |
A Randomized Double-Blinded, Placebo-Controlled Trial of Antibiotic Therapy in Patients With Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level |
- Lower Respiratory Tract Infection
|
- Drug: Azithromycin
- Other: Placebo
- Device: VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)
|
Interventional
|
Not Applicable |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Diagnostic
|
- Clinical improvement: improvement in > / = 2 symptoms or 1 symptom and > / = 1 vital sign abnormality; no deterioration in symptom; no fever; no ambulatory medical facility visit/hospitalization for persistent/worsening LTRI, in Azithromycin group
- Clinical improvement: improvement in > / = 2 symptoms or 1 symptom and > / = 1 vital sign abnormality; no deterioration in symptom; no fever; no ambulatory medical facility visit/hospitalization for persistent/worsening LTRI, in placebo group
- Clinical improvement: improvement in > / = 2 symptoms or 1 symptom (as applicable); no deterioration in symptom; no fever; no ambulatory medical facility visit/hospitalization for persistent/worsening LTRI, in Azithromycin group
- (and 22 more...)
|
420 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03341273 |
15-0020
HHSN272201300015I |
|
December 8, 2017 |
December 29, 2019 |
February 4, 2020 |
November 14, 2017 |
September 17, 2018 |
|
- Emory Vaccine Center - The Hope Clinic
Atlanta, Georgia, United States - Atlanta VA Medical Center - Infectious Diseases Clinic
Decatur, Georgia, United States - Durham VA Medical Center
Durham, North Carolina, United States - (and 2 more...)
|
|
| 13 |
NCT02900820 |
Recruiting |
Safety of Discontinuing Patient Antibiotic Treatment |
- Infectious Diseases
- Respiratory Tract Infections
|
- Other: Discontinuing antibiotic therapy
- Other: Continuing antibiotic therapy
|
Interventional
|
Not Applicable |
- Spanish Society of Family and Community Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Duration of severe symptoms
- Adverse effects of the medication
- Antibiotic consumption
- (and 3 more...)
|
430 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02900820 |
16/101 |
STOP-AB |
January 2017 |
September 2019 |
December 2019 |
September 14, 2016 |
November 1, 2018 |
|
- Coll d'en Rabassa Primary Health Center
Palma de Mallorca, Balearic Islands, Spain - Manso - Via Roma Primary Care Center
Barcelona, Catalonia, Spain - La Marina Primary Care Center
Barcelona, Catalonia, Spain - (and 2 more...)
|
|
| 14 |
NCT01595529 |
Recruiting |
The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children" |
|
- Drug: Cefixime
- Drug: Cephalexin
- Other: Placebo
- Drug: Trimethoprim/Sulfamethoxazole
|
Interventional
|
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Comparison of efficacy based on symptomatic Urinary Tract Infection (UTI) between short-course and standard-course of antibiotics.
- Comparison of number of subjects that have a recurrent infection (includes a relapse UTI or a reinfection) following short-course versus standard-course of antibiotics.
- Comparison of the number of subjects that become colonized with antimicrobial resistant Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) in the gastrointestinal tract following short-course versus standard course of antibiotics.
- (and 3 more...)
|
746 |
All |
2 Months to 10 Years (Child) |
NCT01595529 |
09-0103 |
|
May 18, 2012 |
June 30, 2019 |
December 31, 2019 |
May 10, 2012 |
December 24, 2018 |
|
- Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric
Pittsburgh, Pennsylvania, United States
|
|
| 15 |
NCT03784807 |
Recruiting |
New Strategies for Biofilm Related Infections |
- Prosthetic Joint Infection
|
- Diagnostic Test: synovial calprotectin, confocal laser microscopy
|
Observational
|
|
- Istituto Ortopedico Galeazzi
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Assessment of analytical performance of calprotectin and CLSM for diagnosis of prosthetic joint infections
- Improvement in antibiotic therapy applying data obtained from antibiotic susceptibility testing on biofilm
|
99 |
All |
18 Years and older (Adult, Older Adult) |
NCT03784807 |
Diafilm |
Diafilm |
November 2, 2018 |
September 30, 2020 |
November 30, 2020 |
December 24, 2018 |
December 24, 2018 |
|
- IRCCS Istituto Ortopedico Galeazzi
Milano, MI, Italy
|
|
| 16 |
NCT01871753 |
Recruiting |
The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria |
- Asymptomatic Bacteriuria
- Bacteriuria
- Urinary Tract Infections
- Kidney Transplantation
|
- Other: Anti-Infective Agents
|
Interventional
|
Phase 4 |
- Erasme University Hospital
- University Hospital, Lille
- Universitair Ziekenhuis Brussel
- (and 7 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- cumulative incidence of a first episode of symptomatic urinary tract infection
- incidence of a first episode of pyelonephritis
- clearance of asymptomatic bacteriuria
- (and 10 more...)
|
198 |
All |
18 Years and older (Adult, Older Adult) |
NCT01871753 |
BiRT study
2012-003857-26 |
BiRT |
April 2014 |
June 2019 |
|
June 7, 2013 |
January 31, 2018 |
|
- Universitair Ziekenhuis Antwerpen
Antwerpen, Belgium - Centre Hospitalier Epicura
Baudour, Belgium - Centre Hospitalier Universitaire Brugmann
Brussels, Belgium - (and 12 more...)
|
|
| 17 |
NCT03752424 |
Recruiting |
Topical Silver Nanoparticles for Microbial Activity |
- Foot Infection Fungal
- Infection, Bacterial
|
- Drug: Silver nanoparticles
- Drug: Topical approved anti-microbial gel
|
Interventional
|
Phase 1 |
- Ahmed A. H. Abdellatif
- Al-Azhar University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- The antimicrobial activity of silver nanoparticles in the two groups of control and an infected patient will be determined. Each group will be of 6 volunteers, each one will be controlled for the CTCAE.
- Stable topical anti-microbial silver nanoparticles
|
30 |
All |
20 Years to 60 Years (Adult) |
NCT03752424 |
AlAzharSilver |
|
January 13, 2019 |
January 12, 2020 |
January 11, 2021 |
November 26, 2018 |
November 26, 2018 |
|
- Buraidah Clinic
Buraidah, Al Qassim, Saudi Arabia
|
|
| 18 |
NCT00514098 |
Recruiting |
Observational Study of HIV Infected Women Previously Enrolled in Other Microbicide Trials |
|
|
Observational
|
|
- Microbicide Trials Network
- National Institute of Allergy and Infectious Diseases (NIAID)
- Microbicide Trials Network
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- HIV disease progression comparison
- Virologic and immunologic response comparison
- HIV-1 drug resistance profile comparison
- Sexual behavior and partnership status changes
|
500 |
Female |
Child, Adult, Older Adult |
NCT00514098 |
MTN-015
5UM1AI068633
10529 |
|
August 2008 |
November 2020 |
November 2020 |
August 9, 2007 |
August 30, 2017 |
|
- College of Med. JHU CRS
Blantyre, Malawi - University of North Carolina Lilongwe
Lilongwe, Malawi - Wits Reproductive Health Institute (WRHI)
Johannesburg, Gauteng, South Africa - (and 15 more...)
|
|
| 19 |
NCT03311113 |
Not yet recruiting |
Adherence to Oral Antibiotics In Patients With Osteoarticular Infections |
- Bone and Joint Infection
- Adherence, Medication
|
- Other: Drug adherence questionnaire
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Proportion of patients with high, moderate and poor adherence
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03311113 |
69HCL17_0467 |
OBSAIO |
November 2017 |
November 2018 |
November 2018 |
October 16, 2017 |
October 16, 2017 |
|
- Centre de référence des infections ostéo-articulaires de Lyon
Lyon, France
|
|
| 20 |
NCT02988089 |
Recruiting |
Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment |
- Helicobacter Pylori Infection
- Antimicrobial Susceptibility Testing
|
- Drug: Clarithromycin susceptibility dependant strategy
- Drug: 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )
- Drug: proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
- (and 3 more...)
|
Interventional
|
Phase 4 |
- Shandong University
- Shandong Provincial Hospital
- General Hospital of Jinan Military Region
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Eradication rates in 2 groups
- the rate of improving dyspepsia symptoms after H. pylori eradication
- the rate of adverse events happening
- (and 2 more...)
|
480 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02988089 |
2016SDU-QILU-23 |
|
April 20, 2017 |
September 2017 |
September 2017 |
December 9, 2016 |
April 25, 2017 |
|
- Department of Gastroenterology, Qilu Hospital, Shandong University
Ji'nan, Shandong, China
|
|
| 21 |
NCT03551847 |
Recruiting |
The Effect of Oral Antibiotics on Synovial Fluid and Differential for the Diagnosis of Infection |
|
- Drug: Antibiotic
- Drug: No antibiotics
|
Interventional
|
Not Applicable |
- Rush University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- A change in synovial fluid white blood cell count with antibiotic treatment
- A change in synovial fluid neutrophil percentage with antibiotic treatment
- A change in culture results with antibiotic treatment
|
170 |
All |
18 Years and older (Adult, Older Adult) |
NCT03551847 |
16071701 |
|
November 1, 2017 |
May 1, 2019 |
December 1, 2020 |
June 11, 2018 |
June 11, 2018 |
|
- Rush University medical Center
Chicago, Illinois, United States
|
|
| 22 |
NCT03761043 |
Recruiting |
Nurse Promotion of IV to PO Antimicrobial Conversion |
- Behavior Change
- Bacterial Infections
|
- Behavioral: Professional Behavior Change Intervention
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- IV to PO antimicrobial conversion rate
- Days of IV therapy prior to conversion to PO antimicrobial
- Nurse perceptions of capability, opportunity and motivation to promote IV to PO antimicrobial conversion
|
276 |
All |
19 Years and older (Adult, Older Adult) |
NCT03761043 |
IH1803202 |
FERN-IPO |
January 7, 2019 |
April 2019 |
April 2019 |
December 3, 2018 |
January 15, 2019 |
|
- Kelowna General Hospital
Kelowna, British Columbia, Canada
|
|
| 23 |
NCT03397433 |
Recruiting |
ANti-infective Stewardship Using the Wisca Tool in the Electronic Medical Record |
|
- Other: Information Technology physician assist
|
Interventional
|
Not Applicable |
- NorthShore University HealthSystem Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in length of stay
- Rapid response to initial therapy
- Reduced cost of ancillary testing
- (and 7 more...)
|
6000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03397433 |
EH13-368 |
ANSWER |
June 2015 |
July 2018 |
October 2018 |
January 12, 2018 |
January 12, 2018 |
|
- NorthShore University HealthSystem Research Institute
Evanston, Illinois, United States
|
|
| 24 |
NCT03299387 |
Recruiting |
INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI |
|
- Drug: Nitrofurantoin
- Drug: Gentamicin
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in microbiologic effect of a chronic acute Urinary Tract Infection
- Change in symptomatic relief of a chronic acute Urinary Tract Infection
- To establish the clinical FTE needs for providing urgent intravesical treatments
|
40 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03299387 |
11-002887 |
INSTANT |
June 28, 2017 |
July 1, 2019 |
July 14, 2019 |
October 3, 2017 |
October 3, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 25 |
NCT03221504 |
Recruiting |
7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children |
- Urinary Tract Infections in Children
|
- Other: Longer therapy duration
- Other: Shorter therapy duration
|
Interventional
|
Not Applicable |
- Medical University of Warsaw
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- frequencies of recurrence of UTI
- frequencies of reinfection of UTI
- antibiotic-associated diarrhoea (AAD), compliance
|
221 |
All |
3 Months to 7 Years (Child) |
NCT03221504 |
WUM |
|
January 1, 2018 |
July 31, 2019 |
January 31, 2020 |
July 18, 2017 |
March 20, 2018 |
|
- Children's Hospital for The Medical University of Warsaw
Warsaw, Poland - The Holy Family Specialistic Hospital
Warsaw, Poland
|
|
| 26 |
NCT03349567 |
Recruiting |
Improving Antimicrobial-Prescribing in Emergency Departments |
- Anti-Bacterial Agents
- Respiratory Tract Infections
|
- Behavioral: Audit-and-feedback
|
Interventional
|
Not Applicable |
- Iowa City Veterans Affairs Medical Center
- Merck Sharp & Dohme Corp.
|
U.S. Fed / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Change in antimicrobial-prescribing volume
- Guideline-discordant antimicrobial use
- Late antimicrobial prescription
- (and 3 more...)
|
60 |
All |
Child, Adult, Older Adult |
NCT03349567 |
201708772 |
|
October 9, 2018 |
October 31, 2019 |
December 31, 2019 |
November 21, 2017 |
October 9, 2018 |
|
- Richard Roudebush VAMC
Indianapolis, Indiana, United States - Sioux Falls VA
Sioux Falls, South Dakota, United States
|
|
| 27 |
NCT03832465 |
Not yet recruiting
New |
Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution |
- Helicobacter Pylori Infection
|
- Drug: Levofloxacin film-coated tablet
- Drug: Levofloxacin intravenous solution
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Eradication rate of the intraluminal Levofloxacin therapy
- Incidence of adverse effects of the intraluminal Levofloxacin therapy
- Eradication rates of 7-day or 14-day levofloxacin-containing triple therapy
- The overall eradication rate
|
50 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT03832465 |
18MMHIS168 |
|
February 15, 2019 |
August 14, 2020 |
January 27, 2021 |
February 6, 2019 |
February 15, 2019 |
|
- Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
Taipei, Taiwan
|
|
| 28 |
NCT02645682 |
Recruiting |
The Effects of Anti-infective Central Venous Catheter on Catheter-related Infection in Critically Patients |
|
- Device: anti-infection CVC
- Device: normal CVC
|
Interventional
|
Not Applicable |
- West China Hospital
- Peking Union Medical College Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- catheter-related bloodstream infection
- catheter-related thrombosis
- all cause mortality
|
1818 |
All |
18 Years and older (Adult, Older Adult) |
NCT02645682 |
HC-I-H 1503 |
|
March 2016 |
December 2017 |
December 2018 |
January 5, 2016 |
May 10, 2017 |
|
- Peking Union Medical College Hospital
Beijing, Beijing, China - West China Hospital, Sichuan University
Chengdu, Sichuan, China
|
|
| 29 |
NCT03009045 |
Recruiting |
Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections |
|
|
Interventional
|
Phase 2 |
- Los Angeles Biomedical Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of "moderate" or "serious" adverse events as assessed by MedDRA v18.1
- Number of participants with an outcome of "cure" as defined as no need for further antibiotics beyond the originally planned duration determined by the participant's primary/treating physician.
- Number of participants with treatment-related adverse events as assessed by MedDRA v18.1
|
55 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03009045 |
21814-01 |
|
February 6, 2017 |
July 2018 |
January 2019 |
January 4, 2017 |
May 15, 2018 |
|
- Harbor-UCLA Medical Center
Torrance, California, United States - Los Angeles BioMedical Research Institute (LA BioMed)
Torrance, California, United States
|
|
| 30 |
NCT02920463 |
Recruiting |
DetermInants of Antimicrobial Use aNd De-escalAtion in Critical Care (DIANA) |
|
|
Observational
|
|
- University Hospital, Ghent
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients in which the empirical antibiotic therapy is de-escalated
- Proportion of patients with clinical cure at day 7 in de-escalated patients versus non-deescalated patients
- Antibiotics used in empirical antimicrobial therapy in critically ill patients
- (and 10 more...)
|
2500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02920463 |
EC/2016/0938 |
DIANA |
October 2016 |
July 2018 |
July 2018 |
September 30, 2016 |
May 21, 2018 |
|
- Ghent University Hospital
Ghent, Belgium
|
|
| 31 |
NCT03462459 |
Recruiting |
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection |
- Recurrent Clostridium Difficile Infection
- Clostridium Difficile Infection
|
- Drug: Vancomycin
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
- Indiana University
- Medical College of Wisconsin
- Agency for Healthcare Research and Quality (AHRQ)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Recurrent Clostridium difficile infection (CDI)
- Gut microbiome composition
- Vancomycin-resistant enterococcus (VRE) colonization in patients receiving vancomycin vs. placebo
- Determine whether Clostridium difficile positivity on any stool sample is a predictor of CDI recurrence.
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT03462459 |
2017-0927
1R01HS025713-01 |
|
May 21, 2018 |
December 31, 2021 |
December 31, 2021 |
March 12, 2018 |
June 20, 2018 |
|
- University of Wisconsin-Madison
Madison, Wisconsin, United States
|
|
| 32 |
NCT02832258 |
Recruiting |
Urinary Tract Infection Due to Beta-lactamase-producing Enterobacteriaceae in Children |
|
|
Observational
|
|
- Fouad Madhi
- Centre Hospitalier Intercommunal Creteil
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- First and second lines used antibiotic therapies
- Resistance patterns of ESBL types in the isolates
- Clinical characteristics (fewer, clinical sepsis) of E-ESBL UTI in children
- (and 9 more...)
|
800 |
All |
up to 18 Years (Child, Adult) |
NCT02832258 |
PYELOBLSE |
PYELOBLSE |
March 2014 |
October 2022 |
December 2022 |
July 14, 2016 |
February 6, 2019 |
|
- Antoine Beclère Hospital
Clamart, Ile-de France, France - Jean Verdier Hospital
Bondy, Ile-de-France, France - André Mignot Hospital
Le Chesnay, Ile-de-France, France - (and 22 more...)
|
|
| 33 |
NCT03765528 |
Not yet recruiting |
Impact of Prescription Quality, Infection Control and Antimicrobial Stewardship on Gut Microbiota Domination by Healthcare-Associated Pathogens |
- Patients at High Risk of Antibacterial Treatment Upon Admission
|
|
Observational
|
|
- University Hospital of Cologne
- University Hospital of North Norway
- Karolinska Institutet
- (and 7 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Impact of inappropriate antibacterial prescription on intestinal microbiota domination by healthcare associated pathogens
- Time-point of Intestinal Colonization
- Time-point of Intestinal Domination
- (and 4 more...)
|
1500 |
All |
18 Years and older (Adult, Older Adult) |
NCT03765528 |
PILGRIM |
PILGRIM |
December 1, 2018 |
December 31, 2020 |
March 31, 2021 |
December 5, 2018 |
December 5, 2018 |
|
- University Hospital of Cologne
Cologne, NRW, Germany
|
|
| 34 |
NCT03672630 |
Not yet recruiting |
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease |
- Mycobacterium Avium Complex
- Nontuberculous Mycobacterium Infection
|
- Drug: Azithromycin
- Drug: Ethambutol
- Drug: Rifampin
|
Interventional
|
Phase 2
Phase 3 |
- Kevin Winthrop
- Patient-Centered Outcomes Research Institute
- National Jewish Health
- (and 25 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Acid-fast bacilli (AFB) culture negativity
- Therapy completion
- QOL-B Respiratory Symptoms Score
- (and 5 more...)
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT03672630 |
18819
PCS-2017C2-7764 |
MAC2v3 |
February 28, 2019 |
February 28, 2023 |
February 28, 2023 |
September 14, 2018 |
January 11, 2019 |
|
- University of California, San Diego
San Diego, California, United States - University of California, San Francisco
San Francisco, California, United States - Standford University
Stanford, California, United States - (and 23 more...)
|
|
| 35 |
NCT03221140 |
Recruiting |
Outpatient Parenteral Antimicrobial Therapy (OPAT) |
|
- Drug: Outpatient parenteral antimicrobial therapy
|
Observational
|
|
- University of Lausanne Hospitals
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluation of treatment outcomes
- Evaluation of the incidence of adverse events
- Economic evaluation
|
2000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03221140 |
34/14 |
|
January 1, 2014 |
December 31, 2020 |
December 31, 2021 |
July 18, 2017 |
July 25, 2017 |
|
- Department of Outpatient Care and Community Medicine, University Hospital of Lausanne
Lausanne, Switzerland
|
|
| 36 |
NCT03244917 |
Recruiting |
Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias |
- Dementia
- Infection, Bacterial
|
|
Interventional
|
Not Applicable |
- Hebrew Rehabilitation Center, Boston
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Total antimicrobial use
- Antimicrobial use when minimal criteria are absent
- Burdensome interventions
- Advance care planning
|
480 |
All |
21 Years and older (Adult, Older Adult) |
NCT03244917 |
TRAIN-AD |
TRAIN-AD |
October 15, 2017 |
August 2020 |
March 2021 |
August 10, 2017 |
November 14, 2017 |
|
- Hebrew SeniorLife
Boston, Massachusetts, United States
|
|
| 37 |
NCT03560232 |
Recruiting |
Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens |
- Open Fracture
- Post-Op Wound Infection
|
- Drug: Ceftriaxone
- Drug: Ampicillin/sulbactam
- Drug: Piperacillin/tazobactam
- (and 2 more...)
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Post-surgical site wound infections
- Incidence of acute kidney injury
- Average cost of antibiotic therapy per patient
- Time to antibiotic therapy
|
320 |
All |
18 Years and older (Adult, Older Adult) |
NCT03560232 |
17-028 |
|
July 9, 2018 |
June 2020 |
June 2020 |
June 18, 2018 |
August 31, 2018 |
|
- St. Joseph Warren Hospital
Warren, Ohio, United States - St. Elizabeth Youngstown Hospital
Youngstown, Ohio, United States
|
|
| 38 |
NCT03391076 |
Recruiting |
The Clinical Value of FA in AHLRI Patients |
- Lower Respiratory Tract Infection
|
- Diagnostic Test: FilmArray Respiratory Panel
|
Interventional
|
Not Applicable |
- Bin Cao
- BioMérieux
- Capital Medical University
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Diagnostic
|
- The length (days) of antibiotics therapy in hospital between two groups.
- Antibiotics therapy cost
- Length of hospital stay (LOS) and/or ICU stay
- (and 2 more...)
|
800 |
All |
18 Years and older (Adult, Older Adult) |
NCT03391076 |
20170909 |
FALRI |
September 21, 2017 |
September 30, 2018 |
October 23, 2018 |
January 5, 2018 |
October 9, 2018 |
|
- Chian Japan Friendship Hospital
Beijing, Beijing, China
|
|
| 39 |
NCT01714596 |
Recruiting |
Randomized Trial to Assess PO Versus IV Antibiotics |
|
- Other: PO versus IV antibiotics Route of administration evaluation
|
Interventional
|
Not Applicable |
- Major Extremity Trauma Research Consortium
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary objective: investigate the efficacy of oral (PO) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures or joint fusions.
- Patient Adherence
|
264 |
All |
18 Years to 84 Years (Adult, Older Adult) |
NCT01714596 |
METRC POvIV |
POvIV |
December 3, 2013 |
September 30, 2019 |
September 30, 2020 |
October 26, 2012 |
September 5, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Cedars Sinai Medical Center
Los Angeles, California, United States - Naval Medical Center San Diego
San Diego, California, United States - (and 22 more...)
|
|
| 40 |
NCT03120975 |
Recruiting |
Computerized Antibiotic Stewardship Study |
|
- Other: Computerized decision support and audit & feedback
- Other: Audit & Feedback
- Other: Standard antibiotic stewardship
|
Interventional
|
Not Applicable |
- Benedikt Huttner
- Swiss National Science Foundation
- University of Geneva, Switzerland
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Days of therapy (DOT)/admission
- Days of therapy(DOT)/100 patient days
- Defined daily doses (DDD)/100 patient days (PD) and per admission
- (and 19 more...)
|
5000 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT03120975 |
2017-00454
407240_167079 |
COMPASS |
September 3, 2018 |
December 31, 2019 |
March 31, 2020 |
April 19, 2017 |
February 5, 2019 |
|
- Geneva University Hospitals
Geneva, GE, Switzerland - Ente Ospedaliera Cantonale - Ospedale San Giovanni
Bellinzona, TI, Switzerland - Ente Ospedaliera Cantonale - Ospedale Civico
Lugano, TI, Switzerland
|
|
| 41 |
NCT01760863 |
Recruiting |
Oral Antibiotics After 2-Stage Revision for Infected Total Hip Arthroplasty and Total Knee Arthroplasty |
- Prosthesis-Related Infections
|
|
Interventional
|
Not Applicable |
- Rush University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
|
200 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT01760863 |
11040802 |
|
July 2011 |
December 2018 |
December 2020 |
January 4, 2013 |
June 8, 2018 |
|
- Rush University Medical Center
Chicago, Illinois, United States - Central DuPage Hospital
Winfield, Illinois, United States - Rothman Institute
Philadelphia, Pennsylvania, United States - Vanderbilt
Nashville, Tennessee, United States
|
|
| 42 |
NCT02380352 |
Recruiting |
Short-course Antimicrobial Therapy for Paediatric Respiratory Infections |
- Community-acquired Pneumonia
|
- Drug: Amoxicillin
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Hamilton Health Sciences Corporation
- Children's Hospital of Eastern Ontario
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Early clinical cure (Resolution of tachypnoea, increased work of breathing, and fever)
- Days of adverse reactions
- Days of missed school
- (and 2 more...)
|
270 |
All |
6 Months to 10 Years (Child) |
NCT02380352 |
SAFER 001 PSI |
SAFER |
September 2016 |
August 2019 |
November 2019 |
March 5, 2015 |
August 9, 2018 |
|
- McMaster Children's Hospital
Hamilton, Ontario, Canada - Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
|
|
| 43 |
NCT03745014 |
Not yet recruiting |
Clinical Impact of Fast Phenotypic Antimicrobial Susceptibility Testing on Patients With Bacteremic Urinary Tract Infections |
|
- Diagnostic Test: Accelerate Pheno
- Diagnostic Test: Standard of Care
|
Interventional
|
Not Applicable |
- Accelerate Diagnostics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Desirability of Outcome Ranking (DOOR) - composite outcome
|
420 |
All |
18 Years and older (Adult, Older Adult) |
NCT03745014 |
ECP000002 |
|
December 15, 2018 |
December 15, 2019 |
January 31, 2020 |
November 19, 2018 |
November 19, 2018 |
|
|
|
| 44 |
NCT02951481 |
Recruiting |
Antimicrobial Stewardship Program for Clostridium Difficile Infection. |
- Clostridium Difficile
- Enterocolitis, Pseudomembranous
|
- Behavioral: Systematic evaluation by an ID expert.
|
Observational
|
|
- José María Aguado García, MD, PhD
- Hospital Universitario 12 de Octubre
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- Rate of Clostridium difficile infection recurrence.
- Compliment with clinical practice guidelines for treatment of C. difficile infection.
- Patients with antimicrobial adjustment.
- (and 2 more...)
|
100 |
All |
18 Years to 110 Years (Adult, Older Adult) |
NCT02951481 |
JMA-MET-2016-01 |
PACTA-ICD |
February 8, 2017 |
March 2018 |
December 2018 |
November 1, 2016 |
March 3, 2017 |
|
- Unidad de Enfermedades Infecciosas. Hospital Universitario 12 de Octubre
Madrid, Spain
|
|
| 45 |
NCT02113774 |
Not yet recruiting |
The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients |
- Urinary Tract Infection
- Bacteriuria
- Renal Transplantation
|
- Other: antimicrobial treatment according to in-vitro susceptibility
|
Interventional
|
Phase 4 |
|
Other |
- Primary Purpose: Treatment
|
- development of symptomatic urinary tract infection
- 25% reduction in estimated glomerular filtration rate (eGFR)
|
|
All |
18 Years and older (Adult, Older Adult) |
NCT02113774 |
7687 |
|
April 2014 |
April 2019 |
|
April 15, 2014 |
April 15, 2014 |
|
|
|
| 46 |
NCT03338738 |
Recruiting |
Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria |
- Enterobacterial Infection
|
- Diagnostic Test: Stool culture ans swab
|
Interventional
|
Not Applicable |
- Groupe Hospitalier Paris Saint Joseph
- Hospital Avicenne
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03338738 |
COPROBLSE |
|
July 19, 2018 |
July 31, 2020 |
December 31, 2020 |
November 9, 2017 |
August 8, 2018 |
|
- Groupe Hospitalier Paris Saint Joseph
Paris, Ile-de-France, France
|
|
| 47 |
NCT02809131 |
Recruiting |
Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. |
- Sick Sinus Syndrome
- Complete Heart Block
- Syncope
- Chronic Systolic Heart Failure
|
- Drug: polymixin/bacitracin
- Drug: cephalexin, or levofloxacin, or clindamycin
- Drug: Saline
|
Interventional
|
Phase 3 |
- Vanderbilt University Medical Center
- Thomas Jefferson University
- The Cooper Health System
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of patients with a major CIED infection
- Number of patients with a minor CIED infection
|
1492 |
All |
18 Years and older (Adult, Older Adult) |
NCT02809131 |
150753 |
ENVELOPE |
April 2016 |
June 2019 |
June 2019 |
June 22, 2016 |
April 3, 2018 |
|
- Vanderbilt University Medical Center
Nashville, Tennessee, United States - Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
|
| 48 |
NCT02373280 |
Recruiting |
The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection |
|
- Drug: 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)
- Drug: 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)
- Drug: 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]
- Drug: 7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)
|
Interventional
|
Not Applicable |
- Seoul National University Bundang Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Compare the percentage of participants with successful H. pylori eradication in each groups
|
600 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02373280 |
B-1407/259-005 |
|
August 2014 |
December 2019 |
December 2019 |
February 27, 2015 |
December 19, 2017 |
|
- Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of
|
|
| 49 |
NCT03397615 |
Not yet recruiting |
Effect of Vaginal Douching With Betadine Before CS for Prevention of Post Operative Infections |
|
- Behavioral: Betadine douches
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Postpartum endometritis
- Postoperative wound infection
- Postoperative fever
|
1200 |
Female |
18 Years to 40 Years (Adult) |
NCT03397615 |
16 |
|
January 2018 |
December 2018 |
December 2018 |
January 12, 2018 |
January 12, 2018 |
|
- Kasr Alainy medical school
Cairo, Egypt
|
|
| 50 |
NCT03228108 |
Not yet recruiting |
Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy. |
- Complication
- Infection
- Prostate Cancer
|
- Drug: Ciprofloxacin
- Drug: Trimethoprim/Sulfamethoxazole
- Drug: Fosfomycin
- Drug: Pivmecillinam/augmentin
|
Interventional
|
Phase 4 |
- Radboud University
- ZonMw: The Netherlands Organisation for Health Research and Development
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Any registered clinical infectious complication after prostate biopsy
- Cost of care
- Positive microbiological results
- (and 5 more...)
|
1400 |
Male |
18 Years to 90 Years (Adult, Older Adult) |
NCT03228108 |
pro-SWAP104622 |
pro-SWAP |
October 2017 |
January 2020 |
February 2021 |
July 24, 2017 |
July 24, 2017 |
|
- Catharina Hospital
Eindhoven, Netherlands - Canisius Wilhelmina Hospital
Nijmegen, Netherlands - Radboud University Medical Center
Nijmegen, Netherlands
|
|
| 51 |
NCT02424461 |
Recruiting |
Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection |
- Acute Male Urinary Tract Infection
|
- Drug: Ceftriaxone
- Drug: Ofloxacine
- Drug: Placebo of ofloxacine
|
Interventional
|
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Success defined by resolution of fever
- Intestinal carriage of antimicrobial-resistant Gram-negative bacilli
- Incidence and severity of adverse drug events
- Recurrent UTI
|
400 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02424461 |
P120116
AOM12268 |
PROSTASHORT |
February 2015 |
December 2018 |
December 2018 |
April 23, 2015 |
December 8, 2017 |
|
- Saint Louis hospital
Paris, France
|
|
| 52 |
NCT03788967 |
Not yet recruiting |
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
- Complicated Urinary Tract Infection
- Acute Pyelonephritis
|
- Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
- Drug: Ertapenem
|
Interventional
|
Phase 3 |
- Spero Therapeutics
- Spero Therapeutics
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of patients with overall response (combined clinical cure plus microbiological eradication) at test-of-cure (TOC) in the micro- intent-to-treat (ITT) population
|
1200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03788967 |
SPR994-301 |
ADAPT-PO |
March 2019 |
May 2020 |
June 2020 |
December 28, 2018 |
December 28, 2018 |
|
|
|
| 53 |
NCT03658733 |
Not yet recruiting |
A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection |
- Helicobacter Pylori Infection
|
- Drug: esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
- Drug: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Eradication rates
- The rate of adverse events happening
- The change of dyspepsia symptoms after Helicobacter pylori eradication
- The rate of good compliance
|
120 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03658733 |
2018SDU-QILU-G002 |
|
December 15, 2018 |
August 31, 2019 |
October 31, 2019 |
September 5, 2018 |
December 4, 2018 |
|
- Xiuli Zuo
Jinan, Shandong, China
|
|
| 54 |
NCT02789579 |
Recruiting |
The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy |
- Complication of Surgical Procedure
|
- Drug: levofloxacin
- Drug: Nitrofurantoin
- Drug: cefuroxime
|
Interventional
|
Early Phase 1 |
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Evidence of clinically urinary tract infection confirmed by laboratory examination or urine bacterial culture.
- Evidence of clinically urosepsis confirmed by laboratory examination, urine bacterial culture, and vital signs
|
150 |
All |
16 Years to 75 Years (Child, Adult, Older Adult) |
NCT02789579 |
XH-16-010 |
|
September 2016 |
December 2018 |
December 2018 |
June 3, 2016 |
May 11, 2018 |
|
- Department of Pharmacy, Xinhua Hospital, Shanghai Jiaotong University School of Medicine.Kongjiang Road 1665,
Shanghai, Shanghai, China
|
|
| 55 |
NCT02801253 |
Recruiting |
Cohort of Prosthetic Joint Infections |
- Prosthetic Joint Infection
|
|
Observational
|
|
- Groupe Hospitalier Diaconesses Croix Saint-Simon
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients with hip and knee prosthetic joint reinfection (relapse and new infection) and multi-variable analysis of reinfection risk factors
- Assessment of joint function at one, two, four and 6 years after prosthesis revision with one or two stage exchange arthroplasty.
- Assessment of mechanical failure rate six years after prosthesis revision with one or two stage exchange arthroplasty
- (and 2 more...)
|
400 |
All |
18 Years and older (Adult, Older Adult) |
NCT02801253 |
ID RCB: 2014-A01100-47 |
COPINS |
September 11, 2015 |
September 2019 |
September 2025 |
June 15, 2016 |
February 14, 2018 |
|
- Groupe Hospitalier Diaconesses Croix Saint Simon
Paris, Ile De France, France
|
|
| 56 |
NCT03825874 |
Recruiting
New |
Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children |
- Urinary Tract Infections
- Urinary Tract Infections in Children
|
- Other: Amikacin
- Other: usual antibiotic treatment
|
Observational
|
|
- Centre Hospitalier Intercommunal Creteil
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Presence of E-BLSE in stools
- Type of E-BLSE strain in stools
- Rate of enzymatic resistance of E-BLSE strain in stools
- (and 3 more...)
|
200 |
All |
3 Months to 3 Years (Child) |
NCT03825874 |
MIKA
2017-A02372-51 |
MIKA |
January 18, 2019 |
September 1, 2020 |
December 1, 2020 |
January 31, 2019 |
January 31, 2019 |
|
- Antoine Beclère Hospital
Clamart, Ile-de France, France - Jean Verdier Hospital
Bondy, Ile-de-France, France - André Mignot Hospital
Le Chesnay, Ile-de-France, France - (and 40 more...)
|
|
| 57 |
NCT02359331 |
Recruiting |
The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection |
|
- Procedure: H. pylori culture and antimicrobial susceptibility testing
- Drug: 14 days empirical bismuth quadruple therapy (Proton pump inhibitor)
- Drug: Metronidazole
- (and 5 more...)
|
Interventional
|
Not Applicable |
- Seoul National University Bundang Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Compare the percentage of participants with successful H. pylori eradication in each groups
|
370 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02359331 |
B1408/285-005 |
|
August 2014 |
November 2020 |
December 2020 |
February 10, 2015 |
April 18, 2018 |
|
- Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of
|
|
| 58 |
NCT03346603 |
Recruiting |
Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs |
- Urinary Tract Infections
- Urosepsis
|
- Other: urine culture and susceptibility testing
|
Observational
|
|
- Olive View-UCLA Education & Research Institute
- Centers for Disease Control and Prevention
- IHMA laboratories
|
Other / U.S. Fed |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Prevalence of ESBL-producing Enterobacteriaceae
- Prevalence of carbapenem-resistant Enterobacteriaceae (CRE)
- Prevalence of carbapenem-resistant non fermenting gram negative bacteria
|
650 |
All |
18 Years and older (Adult, Older Adult) |
NCT03346603 |
1057381 |
|
February 8, 2018 |
December 31, 2019 |
December 31, 2020 |
November 17, 2017 |
April 10, 2018 |
|
- Olive View-UCLA Medical Center
Sylmar, California, United States
|
|
| 59 |
NCT03368105 |
Not yet recruiting |
Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain |
|
- Dietary Supplement: Prevention of C. difficile infections using LP299v strain
|
Interventional
|
Not Applicable |
- Medical University of Silesia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Clostridium difficile infection
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT03368105 |
SilesianMUKB-647/2017 |
|
January 1, 2018 |
January 1, 2021 |
July 1, 2021 |
December 11, 2017 |
December 11, 2017 |
|
|
|
| 60 |
NCT03616405 |
Not yet recruiting |
Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection |
- Helicobacter Pylori Infection
|
- Drug: esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Eradication rates
- The rate of adverse events happening
- The rate of improving dyspepsia symptoms after Helicobacter pylori eradication.
- The rate of good compliance
|
60 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03616405 |
2018SDU-QILU-G001 |
|
August 1, 2018 |
May 30, 2019 |
June 30, 2019 |
August 6, 2018 |
August 8, 2018 |
|
- Xiuli Zuo
Jinan, Shandong, China
|
|
| 61 |
NCT03840603 |
Not yet recruiting
New |
Impact on PCT+ FilmArray RP2 Plus Use in LRTI Suspicion in Emergency Department |
- Respiratory Tract Infections
|
- Diagnostic Test: Film Array RP2 Assay guided
|
Interventional
|
Not Applicable |
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Diagnostic
|
- Duration of total antibiotic exposure
- Initiation of an antibiotic therapy
- Protocol "failure" within 15 days of randomization
|
444 |
All |
18 Years and older (Adult, Older Adult) |
NCT03840603 |
2018-A02173-52 |
PROARRAY |
June 1, 2019 |
July 1, 2020 |
January 1, 2021 |
February 15, 2019 |
February 15, 2019 |
|
|
|
| 62 |
NCT03481569 |
Recruiting |
Population Pharmacokinetic-pharmacodynamic (PK-PD) Study of 7 Broad-Spectrum Anti-infective Agents in the Cerebro Spinal Fluid (CSF) of Brain Injured Patients With an External Ventricular Drainage (EVD). |
|
- Other: Blood and cerebrospinal fluid pharmacocinetic samples on one of the seven antibiotics prescribed in routine use
|
Interventional
|
Phase 1 |
- Poitiers University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- CSF-to-plasma area under the unbound concentration-time curve for each antibiotic
- Time > Minimal Inhibitrice Concentration for each antibiotic
- Area Under the Curve / Minimal Inhibitrice Concentration for each antibiotic
- Peak concentration / Minimal Inhibitrice Concentration for each antibiotic
|
175 |
All |
18 Years and older (Adult, Older Adult) |
NCT03481569 |
PKpop LCR |
|
July 6, 2018 |
July 2020 |
October 2020 |
March 29, 2018 |
October 30, 2018 |
|
- CHU of Poitiers
Poitiers, France
|
|
| 63 |
NCT03540706 |
Recruiting |
Impact of the Use of mCRP on the Prescription of Antibiotics in General Practitioners |
- Respiratory Infection
- Respiratory Infections in Children
|
- Diagnostic Test: Care with C-reactive protein assay in micro method
|
Interventional
|
Not Applicable |
- Centre Hospitalier Intercommunal Creteil
- ACTIV
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Rates of antibiotic therapy prescribed
- Rates of antibiotic therapy prescribed in patients aged from 3 to 17 years old
- Rates of antibiotic therapy prescribed in patients aged from 18 to 64 years old
- (and 8 more...)
|
3340 |
All |
3 Years and older (Child, Adult, Older Adult) |
NCT03540706 |
VIP
2018-A00242-53
AOR17072 |
VIP |
May 1, 2018 |
August 31, 2020 |
December 2020 |
May 30, 2018 |
February 1, 2019 |
|
- 22 rue de Silly
Boulogne, France - 25 avenue des frères Lumière
Cormeilles-en-Parisis, France - 8 Rue Saint-Exupéry
Meudon La Forêt, France - (and 9 more...)
|
|
| 64 |
NCT03697993 |
Recruiting |
Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS) |
|
- Drug: Fosfomycin tromethamine
- Drug: Levofloxacin
|
Interventional
|
Phase 4 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The difference in the proportion of subjects achieving treatment success at Test of Cure (TOC) between Strategy 1 arm and Strategy 2 arm
- The proportion of subjects achieving treatment success at Test of Cure (TOC) in Strategy 1 arm
- The proportion of subjects achieving treatment success at Test of Cure (TOC) in Strategy 2 arm
- (and 12 more...)
|
634 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03697993 |
15-0045
HHSN272201300018I |
|
November 7, 2018 |
January 30, 2021 |
January 30, 2021 |
October 5, 2018 |
February 1, 2019 |
|
- University of California Los Angeles - Olive View Medical Center
Sylmar, California, United States - Harbor UCLA Medical Center - Medicine - Infectious Diseases
Torrance, California, United States - Emory Vaccine Center - The Hope Clinic
Decatur, Georgia, United States - (and 9 more...)
|
|
| 65 |
NCT02865616 |
Recruiting |
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI) |
- Clostridium Difficile Infection
|
- Drug: MET-2
- Drug: Vancomycin
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To demonstrate clinical resolution of diarrhea with no CDI relapse,
- Incidence of adverse events (safety and tolerability)
- number of bowel movements (overall well-being)
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02865616 |
MET-2-101 |
|
October 27, 2017 |
March 15, 2018 |
December 2018 |
August 12, 2016 |
December 7, 2017 |
|
- Queen's University, Kingston General Hospital
Kingston, Ontario, Canada
|
|
| 66 |
NCT03005379 |
Recruiting |
Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH) |
- Clostridium Difficile Infection
|
- Drug: Fecal Microbiota Therapy (FMT)
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Recurrent CDI (definite or probable) or death
- Recurrent CDI (definite or possible), or death
- Quality of Life
- (and 7 more...)
|
390 |
All |
18 Years and older (Adult, Older Adult) |
NCT03005379 |
2004 |
MATCH |
November 15, 2018 |
May 30, 2022 |
October 30, 2023 |
December 29, 2016 |
December 11, 2018 |
|
- Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota, United States
|
|
| 67 |
NCT03308253 |
Recruiting |
Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection |
|
- Device: Stimulan Rapid Cure
- Drug: Vancomycin
- Drug: Tobramycin
- Other: Standard of Care
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Surgical Site Infection
- Wound Complication Rate
- Surgical Graft Infection Rate
- Bacterial Resistance
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03308253 |
Antimicrobial Beads |
|
July 16, 2018 |
June 2019 |
July 2019 |
October 12, 2017 |
July 19, 2018 |
|
- Hamilton General Hospital
Hamilton, Ontario, Canada
|
|
| 68 |
NCT03732365 |
Not yet recruiting |
Phase 2 Randomized Study to Compare Ultrasonic Drug Delivery to Standard of Care for the Treatment of Infections in Non-Healing Wounds |
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- Non-healing Wound
|
- Combination Product: Ultrasonic Drug Delivery
- Drug: Standard of Care Antibiotic Treatment
|
Interventional
|
Phase 2 |
- Sonescence, Inc.
- University of Southern California
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Wound healing and eligibility for grafting
- Reduction or elimination of pain
- Clinical signs and symptoms of infection will be assessed
|
30 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03732365 |
SON2018-001 |
|
February 1, 2019 |
January 31, 2020 |
July 31, 2020 |
November 6, 2018 |
November 6, 2018 |
|
|
|
| 69 |
NCT02996656 |
Recruiting |
Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery |
- Propionibacterium Infection
|
- Drug: Cefazolin
- Drug: Ceftriaxone
|
Interventional
|
Not Applicable |
- Université de Montréal
- Tornier, Inc.
- Hopital du Sacre-Coeur de Montreal
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Skin Biopsy
- MRSA observance
- Infection
- (and 3 more...)
|
88 |
All |
18 Years and older (Adult, Older Adult) |
NCT02996656 |
PAPA |
PAPA |
December 2016 |
December 2020 |
December 2021 |
December 19, 2016 |
March 12, 2018 |
|
- Hôpital du Sacré-Cœur de Montréal
Montréal, Quebec, Canada
|
|
| 70 |
NCT03343288 |
Recruiting |
Silver Doped Ceramic Coated Orthopedic Implants |
- Implant Site Infection
- Implant Infection
|
- Device: Silver doped hydroxyapatite coated implants
|
Interventional
|
Not Applicable |
- Eskisehir Osmangazi University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of pin site with positive culture resuls
- Number of patient with elevated level of serum ALT levels
- Number of patient with elevated BUN levels
- Number of patient with elevated blood silver
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03343288 |
315S101 |
|
March 15, 2017 |
March 15, 2020 |
March 15, 2020 |
November 17, 2017 |
November 17, 2017 |
|
- Eskisehir Osmangazi University Hospital
Eskişehir, Turkey
|
|
| 71 |
NCT02354144 |
Recruiting |
Lubricant Investigation in Men to Inhibit Transmission of HPV Infection |
- Human Papillomavirus Infection
|
- Other: Carrageenan-based gel
- Other: Control gel
|
Interventional
|
Phase 2
Phase 3 |
- McGill University
- Université de Montréal
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Presence of a newly detected anal infection of a specific HPV type in a man who was negative for that HPV type at enrolment
- Clearance of anal type-specific HPV infections found at baseline
- Patient adherence, measured via questionnaires and review of patient adverse event reports.
|
380 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02354144 |
A10-M98-14B
CIHR-MOP-137066
CCSRI-703032 |
LIMIT-HPV |
February 2016 |
October 2019 |
December 2019 |
February 3, 2015 |
May 9, 2018 |
|
- McGill University - Division of Cancer Epidemiology
Montreal, Quebec, Canada
|
|
| 72 |
NCT01792804 |
Recruiting |
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options |
- Staphylococcus Aureus Infection
|
- Drug: Trimethoprim-Sulfamethoxazole
- Drug: Clindamycin
- Drug: Linezolid
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Heinrich-Heine University, Duesseldorf
- German Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- SAB-related complications
- Length of hospital stay
- Survival
- Complications of intravenous therapy
|
215 |
All |
18 Years and older (Adult, Older Adult) |
NCT01792804 |
Uni-Koeln-1400
2013-000577-77 |
SABATO |
December 2013 |
October 2019 |
October 2019 |
February 15, 2013 |
October 22, 2018 |
|
- Annecy
Annecy, France - Chambéry
Chambéry, France - Grenoble
Grenoble, France - (and 39 more...)
|
|
| 73 |
NCT03545373 |
Not yet recruiting |
Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study) |
- Tuberculosis
- Respiratory Tract Infections
- Pneumonia
|
- Drug: Azithromycin
- Drug: Amoxicillin
|
Interventional
|
Phase 3 |
- London School of Hygiene and Tropical Medicine
- University of Malawi College of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Diagnostic accuracy of trial-of-antibiotics: Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 against a mycobacteriology reference standard.
- Overall clinical benefit of empirical antibiotic treatment in primary care participants with chronic cough: proportion of participants experiencing adverse clinical outcomes
- Impact of trial-of-antibiotics on antimicrobial resistance
- (and 2 more...)
|
1875 |
All |
18 Years and older (Adult, Older Adult) |
NCT03545373 |
15232 |
ACT-TB |
November 2018 |
November 2019 |
December 2019 |
June 4, 2018 |
September 13, 2018 |
|
|
|
| 74 |
NCT03666195 |
Not yet recruiting |
The Anti-microbial Effect of Titanium Dioxide Nano Particles in Complete Dentures Made for Edentulous Patients |
- Candida Infection
- Denture Stomatitis
|
- Combination Product: Titanium Dioxide Nanoparticles
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
|
20 |
All |
40 Years to 70 Years (Adult, Older Adult) |
NCT03666195 |
Mona's Protocol |
|
October 15, 2018 |
December 15, 2018 |
January 15, 2019 |
September 11, 2018 |
September 11, 2018 |
|
|
|
| 75 |
NCT01821664 |
Recruiting |
Vascular Graft Infections |
- Prosthetic Vascular Graft Infection
|
- Device: Prosthetic vascular graft
|
Observational
|
|
- University of Zurich
- Schweizerischer Nationalfonds
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Vascular graft infection
- Bleeding
- Foreign body reaction
- All cause- mortality
|
1800 |
All |
18 Years and older (Adult, Older Adult) |
NCT01821664 |
KEK-ZH-Nr. 2012-0583 |
VASGRA |
May 2013 |
March 2023 |
March 2023 |
April 1, 2013 |
May 6, 2015 |
|
- University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology
Zurich, ZH, Switzerland
|
|
| 76 |
NCT03550911 |
Not yet recruiting |
Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA) |
- Bone Infection
- Joint Infection
|
- Other: Biological Collection From Samples From The Gut Microbiota
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Biological Collection From Samples From The Gut Microbiota
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT03550911 |
69HCL18_0014 |
|
June 2018 |
June 2021 |
June 2021 |
June 8, 2018 |
June 8, 2018 |
|
- Centre de référence des infections ostéo-articulaires de Lyon - Hôpital de la Croix-Rousse
Lyon, France
|
|
| 77 |
NCT03543436 |
Not yet recruiting |
Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections |
|
- Drug: Temocillin
- Drug: meropenem or imipenem
|
Interventional
|
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
- Groupe Hospitalier Paris Saint Joseph
- French National Network of Clinical Research in Infectious Diseases (RENARCI)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical and microbiological cure
- Early microbiological eradication
- Frequency of oral antibiotic switch in both arms (temocillin vs. carbapenem)
- (and 6 more...)
|
350 |
All |
18 Years and older (Adult, Older Adult) |
NCT03543436 |
P 160910J
2017-001257-14 |
TEMO-CARB |
July 2018 |
January 2020 |
July 2020 |
June 1, 2018 |
June 8, 2018 |
|
- CHU de Martinique
Fort-de-france, Martinique, France - CHU de Grenoble Hospital
Grenoble, France - CHRU de Lille
Lille, France - (and 8 more...)
|
|
| 78 |
NCT03262142 |
Recruiting |
Targeted AntiBiotics for Chronic Obstructive Pulmonary Disease |
- COPD
- Respiratory Tract Infections
- Pseudomonas Aeruginosa
|
- Drug: Piperacillin/tazobactam
- Drug: Ciprofloxacin
|
Interventional
|
Phase 4 |
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Time to systemic corticosteroid and/or antibiotic requiring AECOPD (in both primary and secondary sector) or death.
- Alive and without AECOPD
- Death
- (and 8 more...)
|
150 |
All |
40 Years and older (Adult, Older Adult) |
NCT03262142 |
coptrin2 |
Target-ABC |
January 10, 2018 |
December 2021 |
December 2021 |
August 25, 2017 |
February 20, 2018 |
|
- Herlev and Gentofte Hospital
Hellerup, Copenhagen, Denmark - Nordsjællands Hospital
Hillerød, Denmark
|
|
| 79 |
NCT03333304 |
Recruiting |
A Clinical Trial of Procalcitonin-guided Antimicrobial Therapy in Sepsis |
|
- Diagnostic Test: Procalcitonin measurement
|
Interventional
|
Not Applicable |
- Hellenic Institute for the Study of Sepsis
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The change of infection-associated adverse events rate. The infection-associated adverse events rate are any case of Clostridium Difficile Infection (CDI) or infection by MDR or infection-related death.
- Infection-associated adverse events rate
- Clostridium difficile Infection
- (and 8 more...)
|
280 |
All |
18 Years and older (Adult, Older Adult) |
NCT03333304 |
PROGRESS |
PROGRESS |
October 24, 2017 |
April 23, 2019 |
July 23, 2019 |
November 6, 2017 |
January 9, 2018 |
|
- 1st Department of Internal Medicine, General Hospital of Athens "G. Gennimatas"
Athens, Greece - 4th Department of Internal Medicine, Attikon University Hospital
Athens, Greece - 2nd Department of internal Medicine, General Hospital of Attiki "Sismanogleio"
Athens, Greece - (and 3 more...)
|
|
| 80 |
NCT03218800 |
Recruiting |
Ertapenem Administered Subcutaneously Versus Intravenously |
|
- Combination Product: Ertapenem
|
Interventional
|
Phase 3 |
- Instituto Nacional de Cancer, Brazil
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- microbiological cure
- adverse events
- clinical response
|
106 |
All |
18 Years and older (Adult, Older Adult) |
NCT03218800 |
Ertapsubcut |
|
June 1, 2017 |
December 2020 |
December 2020 |
July 17, 2017 |
August 7, 2018 |
|
- INCA Instituto Nacional do Cancer
Rio de Janeiro, Brazil
|
|
| 81 |
NCT03574090 |
Not yet recruiting |
Study the Efficacy of Topical Antibiotherapy in the Prophylaxis of Incisional Surgical Infection in Urgent Surgery |
- Surgical Wound Infection
- Postoperative Wound Infection
- Postoperative Wound Infection Superficial Incisional
- Preventive Therapy
|
- Drug: Amoxicillin Clavulanate
- Drug: Physiological Saline
|
Interventional
|
Phase 4 |
- Universitat Internacional de Catalunya
- Hospital de Granollers
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Evaluation of the effect of topical antibiotic prophylaxis on the incidence of SSI
- reduction of hospital stay
- Bacterial charge
- Bacterial resistance
|
140 |
All |
18 Years and older (Adult, Older Adult) |
NCT03574090 |
1234 |
PROFITOP |
July 15, 2018 |
June 15, 2020 |
August 15, 2020 |
June 29, 2018 |
June 29, 2018 |
|
|
|
| 82 |
NCT02901717 |
Recruiting |
Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI |
- Catheter-related Infections
|
- Drug: Mino-Lok
- Drug: Antibiotic lock
|
Interventional
|
Phase 3 |
- Leonard-Meron Biosciences, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of subjects deemed successfully treated at the end of the study period
- Proportion of subjects with a response of Clinical Cure at End of Treatment.
- Proportion of subjects in the MITT and CE Populations with a response of microbiological eradication.
- (and 2 more...)
|
700 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT02901717 |
MDA-2013-0039 |
|
February 13, 2018 |
June 2019 |
September 2019 |
September 15, 2016 |
July 10, 2018 |
|
- University of Colorado Denver
Aurora, Colorado, United States - Georgetown University Hospital
Washington, District of Columbia, United States - University of Chicago
Chicago, Illinois, United States - (and 9 more...)
|
|
| 83 |
NCT03544203 |
Recruiting |
Multicentre Observational Study on Community Acquired Intraabdominal Infections Management |
- Intraabdominal Infections
|
|
Observational
|
|
- Centre Hospitalier Universitaire de Nīmes
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03544203 |
2017-A03407-46 |
PERICOM |
April 1, 2018 |
February 28, 2019 |
April 30, 2019 |
June 1, 2018 |
January 11, 2019 |
|
- CHU d'Amiens
Amiens, France - CHU Angers
Angers, France - Hia Percy
Clamart, France - (and 10 more...)
|
|
| 84 |
NCT03685071 |
Not yet recruiting |
Prognostic Value of Complete Blood Count in Severe Infections |
|
- Other: role of CBC as prognostic tool in sepsis.
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- prognosis of outcome in patients suffering from severe infections in PICU by using CBC .
|
100 |
All |
up to 18 Years (Child, Adult) |
NCT03685071 |
PVCCSFSI |
|
December 1, 2018 |
November 30, 2019 |
June 1, 2020 |
September 26, 2018 |
September 26, 2018 |
|
|
|
| 85 |
NCT02283112 |
Recruiting |
Validation of Drug Assays in Various Biological Matrices |
|
- Other: antivirals, antimicrobials, oral contraceptive, erectile dysfunction agents
|
Observational
|
|
- Helen Reynolds
- University of Liverpool
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To measure drug concentrations using high performance liquid chromatography -tandem mass spectrometry (HPLC-MS/MS) (accuracy and precision of assays that measure drug concentrations)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02283112 |
RLUH 4520 |
|
October 2014 |
September 2019 |
September 2019 |
November 5, 2014 |
February 28, 2018 |
|
- Royal Liverpool & Broadgreen Univeristy Hospitals NHS Trust
Liverpool, United Kingdom
|
|
| 86 |
NCT03244644 |
Recruiting |
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) |
- Clostridium Difficile Infection
|
- Drug: RBX2660
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Efficacy of RBX2660 compared to Placebo measured at 8 weeks
- Number of subjects with adverse events through 6 months
- Health Related Quality of Life (HRQOL) Assessment
|
270 |
All |
18 Years and older (Adult, Older Adult) |
NCT03244644 |
2017-01 |
|
July 31, 2017 |
June 2019 |
December 2019 |
August 9, 2017 |
December 4, 2018 |
|
- Athens
Athens, Alabama, United States - Dothan
Dothan, Alabama, United States - Phoenix
Phoenix, Arizona, United States - (and 41 more...)
|
|
| 87 |
NCT03321799 |
Recruiting |
Comparison of Negative Pressure Wound Therapy Versus Conventional Dressings for the Prevention of Wound Complications After Revision THA |
|
- Device: Negative Pressure Wound Therapy (NPWT)
- Device: Sterile Antimicrobial Dressings
|
Interventional
|
Phase 1 |
- Rush University Medical Center
- KCI USA, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Wound complications
- Reoperation
- Cost comparison
|
201 |
All |
18 Years and older (Adult, Older Adult) |
NCT03321799 |
16111608 |
|
April 28, 2017 |
April 28, 2020 |
October 28, 2020 |
October 26, 2017 |
June 11, 2018 |
|
- Rush University Medical Center
Chicago, Illinois, United States
|
|
| 88 |
NCT03488355 |
Not yet recruiting |
Modified Reporting From Indwelling Catheters |
|
- Other: Modified laboratory report
|
Interventional
|
Not Applicable |
- Memorial University of Newfoundland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Treatment
|
- Proportion of inappropriate antibiotic therapy prescribed by physicians (efficacy)
- Adverse events (safety)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03488355 |
MUN-3 |
|
October 2018 |
February 2019 |
March 2019 |
April 5, 2018 |
August 16, 2018 |
|
- Health Sciences Center
Saint John's, Newfoundland and Labrador, Canada
|
|
| 89 |
NCT03611634 |
Recruiting |
Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine |
|
- Other: BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- BIOLOGICAL COLLECTION FROM SAMPLES FROM THE GUT MICROBIOTE
|
20 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT03611634 |
18-126 |
|
July 19, 2018 |
July 19, 2021 |
July 19, 2021 |
August 2, 2018 |
January 16, 2019 |
|
- Hospices Civils de Lyon
Lyon, France
|
|
| 90 |
NCT03250104 |
Recruiting |
Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives |
- Clostridium Difficile Infection
- VRE Infection
- Nosocomial Infection
- MRGN Bacteria
|
- Other: Infection Control
- Other: Antibiotic Stewardship
|
Observational
|
|
- University Hospital of Cologne
- Charite University, Berlin, Germany
- University Hospital Freiburg
- (and 3 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- CDI incidence
- Effectiveness of IC bundle through incidence of CDI or BSI by VRE and MRGN
- PPI usage
- (and 4 more...)
|
80000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03250104 |
TTU HAARBI 8.810 |
ABSOLUTE |
November 2016 |
December 2018 |
December 2020 |
August 15, 2017 |
October 16, 2018 |
|
- University Hospital of Cologne
Cologne, NRW, Germany
|
|
| 91 |
NCT03595566 |
Not yet recruiting |
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
- Clostridium Difficile Infection
|
- Drug: ridinilazole
- Drug: vancomycin
|
Interventional
|
Phase 3 |
- Summit Therapeutics
- Summit Therapeutics
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sustained clinical response defined as clinical cure at the Assessment of Cure (AOC) visit and no recurrence of CDI within 30 days post end of treatment (EOT)
- Clinical cure at Assessment of Cure (AOC) visit
- Sustained clinical response over 60 days
- (and 2 more...)
|
680 |
All |
18 Years and older (Adult, Older Adult) |
NCT03595566 |
SMT19969/C005 |
Ri-CoDIFy 2 |
March 2019 |
March 2021 |
May 2021 |
July 23, 2018 |
July 23, 2018 |
|
|
|
| 92 |
NCT03595553 |
Not yet recruiting |
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
- Clostridium Difficile Infection
|
- Drug: ridinilazole
- Drug: vancomycin
|
Interventional
|
Phase 3 |
- Summit Therapeutics
- Summit Therapeutics
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sustained clinical response defined as clinical cure at the Assessment of Cure (AOC) visit and no recurrence of CDI within 30 days post end of treatment (EOT)
- Clinical cure at Assessment of Cure (AOC) visit
- Sustained clinical response over 60 days
- (and 3 more...)
|
680 |
All |
18 Years and older (Adult, Older Adult) |
NCT03595553 |
SMT19969/C004 |
Ri-CoDIFy 1 |
March 2019 |
March 2021 |
May 2021 |
July 23, 2018 |
July 23, 2018 |
|
|
|
| 93 |
NCT03744728 |
Not yet recruiting |
Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures |
|
- Diagnostic Test: Accelerate PhenoTest™ BC kit
- Diagnostic Test: Standard of Care
|
Interventional
|
Not Applicable |
- Accelerate Diagnostics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Duration of anti-pseudomonal β-lactam therapy
- Duration of anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy
|
466 |
All |
18 Years and older (Adult, Older Adult) |
NCT03744728 |
ECP000001 |
|
December 2018 |
July 2019 |
August 2019 |
November 16, 2018 |
November 16, 2018 |
|
|
|
| 94 |
NCT03151603 |
Recruiting |
Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial |
|
- Drug: Arctuvan
- Drug: Fosfomycin
- Drug: Placebo to Arctuvan
- Drug: Placebo to Fosfomycin
|
Interventional
|
Phase 4 |
- University Medical Center Goettingen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- antibiotic courses
- symptom burden
- early relapses
- (and 21 more...)
|
430 |
Female |
18 Years to 75 Years (Adult, Older Adult) |
NCT03151603 |
01579 |
REGATTA |
May 3, 2017 |
May 2019 |
July 2020 |
May 12, 2017 |
June 5, 2017 |
|
- General Practice Aden
Braunschweig, Germany - General Practice Scheffer
Braunschweig, Germany - General Practice Coutelle
Bremen, Germany - (and 31 more...)
|
|
| 95 |
NCT03543605 |
Not yet recruiting |
Clinical/Microbiological Impact of a Specific Antimicrobial Stewardship Program for Nursing Homes |
- Human Microbiome
- Antibiotic Resistant Infection
- Nursing Homes
|
- Behavioral: PROA Experimental
- Other: PROA Control
|
Interventional
|
Not Applicable |
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Change of Total antimicrobial pressure
- Antimicrobials adverse events
- Incidence of infections by multiresistant bacteria
- Incidence of infections of C. difficile
|
2220 |
All |
Child, Adult, Older Adult |
NCT03543605 |
PROA-SENIOR (PRO-FIS-2017-01) |
PROA-SENIOR |
March 1, 2019 |
June 1, 2020 |
June 1, 2020 |
June 1, 2018 |
February 15, 2019 |
|
- Virgen del Rocío University Hospital
Seville, Spain
|
|
| 96 |
NCT03761264 |
Recruiting |
Systemic and Local Antimicrobials in the Management of Dental Abscess in Children |
|
- Drug: Odontopaste®
- Drug: Pulpdent
- Drug: Amoxicillin
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in Wong Baker Faces Pain Rating Scale of Pain Score at Day 3, Day 5 or 7
- Mean Change From Baseline in Visual Rating Scale of Swelling Score at Days 3, 5 or 7
- Mean Change From Baseline in Regional Lymphadenitis Score at Days 3, 5 or 7
- (and 8 more...)
|
120 |
All |
3 Years to 11 Years (Child) |
NCT03761264 |
RP053A-17HTM |
|
September 18, 2018 |
December 15, 2019 |
January 1, 2020 |
December 3, 2018 |
December 3, 2018 |
|
- University of Malaya
Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
|
|
| 97 |
NCT03217552 |
Recruiting |
The Performance of the Mologic Biomarker Panel in Infection |
|
- Diagnostic Test: Mologic Biomarker Panel
|
Observational
|
|
- Mologic Ltd
- University College London Hospitals
- Innovate UK
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Biomarkers and results from routine clinical testing for infection
|
600 |
All |
18 Years and older (Adult, Older Adult) |
NCT03217552 |
CN010 |
|
November 26, 2017 |
April 2019 |
July 2019 |
July 14, 2017 |
March 29, 2018 |
|
- University College London Hospital
London, United Kingdom
|
|
| 98 |
NCT03535324 |
Recruiting |
Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT) |
- Antibiotic Resistant Infection
|
- Behavioral: PROA for optimization
- Other: Control
|
Interventional
|
Not Applicable |
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Days of treatment (DDT)
- Defined Daily Doses (DDDS)
- 30-day mortality
- (and 3 more...)
|
800 |
All |
18 Years and older (Adult, Older Adult) |
NCT03535324 |
NO-BACT (FIS-ANT-2018-01) |
NO-BACT |
October 5, 2018 |
June 2020 |
December 2020 |
May 24, 2018 |
February 15, 2019 |
|
- Puerta del Mar Hospital
Cadiz, Spain - Virgen Macarena Hospital
Seville, Spain - Lozano Blesa Hospital
Zaragoza, Spain
|
|
| 99 |
NCT02684422 |
Recruiting |
Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF) |
- Methicillin-Resistant Staphylococcus Aureus
- Cystic Fibrosis
|
- Other: Intervention N/A. Observational study
|
Observational
|
|
- University of North Carolina, Chapel Hill
- University of Washington
- University of Alabama at Birmingham
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Changes in presence of hypermutable MRSA isolates post-therapy compared to pre-therapy.
- Other MRSA characteristics in sputum
- Clinical improvement with therapy
|
100 |
All |
4 Years to 99 Years (Child, Adult, Older Adult) |
NCT02684422 |
15-0636 |
TRI-STAR |
July 2015 |
December 2019 |
December 2019 |
February 18, 2016 |
May 4, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States - University of Washington
Seattle, Washington, United States
|
|
| 100 |
NCT03462160 |
Not yet recruiting |
Effectiveness of Probiotics Prophylaxis of Urinary Tract Infections in Children |
- Prevention of Urinary Tract Infections in Children
|
- Other: Placebo control group
- Dietary Supplement: Probiotic experimental group
|
Interventional
|
Not Applicable |
- Medical University of Warsaw
- Miralex Sp. z o.o.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- frequencies of recurrence of UTI
- frequencies of hospitalization due to UTI
- the number of days of antibiotic therapy due to UTI
|
106 |
All |
3 Years to 18 Years (Child, Adult) |
NCT03462160 |
UTI probiotic |
|
April 1, 2018 |
April 1, 2019 |
September 1, 2019 |
March 12, 2018 |
March 12, 2018 |
|
- Children's Hospital for The Medical University of Warsaw
Warsaw, Poland
|
|
Create an RSS feed from your search for:
Download the search results for: